Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Metformin Use to Reduce Disparities in Newly Diagnosed Breast Cancer Response to Neoadjuvant Treatment

NCT04741204 is registered in ClinicalTrials.gov with Woman's as lead sponsor.

NCT NCT04741204
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04741204 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Metformin Use to Reduce Disparities in Newly Diagnosed Breast Cancer Response to Neoadjuvant Treatment
Lead sponsor
Woman's
Phase
Phase 4
Overall status
Withdrawn
Start date
September 30, 2022
Completion date
September 30, 2022
Enrollment
0 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

breast cancer stage, insulin resistance, racial bias